EP4495142A3 - Bispecific antigen binding construct - Google Patents

Bispecific antigen binding construct Download PDF

Info

Publication number
EP4495142A3
EP4495142A3 EP24204244.8A EP24204244A EP4495142A3 EP 4495142 A3 EP4495142 A3 EP 4495142A3 EP 24204244 A EP24204244 A EP 24204244A EP 4495142 A3 EP4495142 A3 EP 4495142A3
Authority
EP
European Patent Office
Prior art keywords
antigen binding
bispecific antigen
bispecific
binding construct
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP24204244.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4495142A2 (en
Inventor
Christophe Blanchetot
Sebastian VAN DER WONING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX BVBA
Original Assignee
ArgenX BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64959348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP4495142(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ArgenX BVBA filed Critical ArgenX BVBA
Publication of EP4495142A2 publication Critical patent/EP4495142A2/en
Publication of EP4495142A3 publication Critical patent/EP4495142A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP24204244.8A 2017-12-22 2018-12-21 Bispecific antigen binding construct Withdrawn EP4495142A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762609523P 2017-12-22 2017-12-22
PCT/EP2018/086755 WO2019122409A1 (en) 2017-12-22 2018-12-21 Bispecific antigen binding construct
EP18830279.8A EP3728328B1 (en) 2017-12-22 2018-12-21 Bispecific antigen binding construct

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP18830279.8A Division EP3728328B1 (en) 2017-12-22 2018-12-21 Bispecific antigen binding construct

Publications (2)

Publication Number Publication Date
EP4495142A2 EP4495142A2 (en) 2025-01-22
EP4495142A3 true EP4495142A3 (en) 2025-05-07

Family

ID=64959348

Family Applications (2)

Application Number Title Priority Date Filing Date
EP24204244.8A Withdrawn EP4495142A3 (en) 2017-12-22 2018-12-21 Bispecific antigen binding construct
EP18830279.8A Revoked EP3728328B1 (en) 2017-12-22 2018-12-21 Bispecific antigen binding construct

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP18830279.8A Revoked EP3728328B1 (en) 2017-12-22 2018-12-21 Bispecific antigen binding construct

Country Status (9)

Country Link
US (2) US12071486B2 (https=)
EP (2) EP4495142A3 (https=)
JP (2) JP7657591B2 (https=)
CN (1) CN111448217A (https=)
AU (1) AU2018387829B2 (https=)
CA (1) CA3079793A1 (https=)
DK (1) DK3728328T5 (https=)
IL (1) IL274676A (https=)
WO (1) WO2019122409A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022525275A (ja) * 2019-03-28 2022-05-12 エービー ストゥーディオ インコーポレイテッド ヘテロ多量体タンパク質及びその使用法
CN114981308A (zh) * 2020-01-19 2022-08-30 南京金斯瑞生物科技有限公司 多特异性抗密蛋白-18.2构建体及其用途
GB202203269D0 (en) 2022-03-09 2022-04-20 Argenx Iip Bv TGF-Beta antibodies
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
AU2024210302A1 (en) * 2023-01-20 2025-09-04 Invetx, Inc. Bispecific binding agents for use in companion animals

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100331527A1 (en) * 2009-06-26 2010-12-30 Regeneron Pharmaceuticals, Inc. Readily Isolated Bispecific Antibodies with Native Immunoglobulin Format
WO2013064701A2 (en) * 2011-11-03 2013-05-10 Argen-X B.V. Bispecific antibodies and methods for isolating same
WO2014022540A1 (en) * 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
WO2014124326A1 (en) * 2013-02-08 2014-08-14 Stem Centrx, Inc. Novel multispecific constructs
WO2015033223A2 (en) * 2013-09-03 2015-03-12 Novimmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
WO2016086189A2 (en) * 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
WO2016086186A2 (en) * 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies including binding to cd8
WO2017218707A2 (en) * 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
BR9813276A (pt) 1997-10-27 2000-08-22 Unilever Nv Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
WO2009040562A1 (en) 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
AU2008328726B2 (en) 2007-11-30 2014-06-12 Glaxo Group Limited Antigen-binding constructs
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
HRP20170374T1 (hr) 2008-09-26 2017-05-05 Ucb Biopharma Sprl Biološki proizvodi
BRPI1014449A2 (pt) 2009-04-07 2017-06-27 Roche Glycart Ag anticorpos biespecíficos anti-erbb-2/ anti-c-met.
GB2476681B (en) * 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
US10689447B2 (en) * 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
JP2014515598A (ja) 2011-03-10 2014-07-03 エイチシーオー アンティボディ， インク． 二重特異性三鎖抗体様分子
US9683052B2 (en) 2011-03-25 2017-06-20 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
CA2854806A1 (en) 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
PT2825559T (pt) 2012-03-13 2019-06-07 Novimmune Sa Anticorpos biespecíficos prontamente isolados com formato de imunoglobulina nativo
DK2847231T3 (da) 2012-05-10 2019-10-14 Bioatla Llc Multispecifikke monoklonale antistoffer
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP3878964A1 (en) 2012-11-27 2021-09-15 Ajou University Industry-Academic Cooperation Foundation Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
AU2014236769B2 (en) 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US10858417B2 (en) * 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
CN105814082A (zh) 2013-09-26 2016-07-27 埃博灵克斯股份有限公司 双特异性纳米抗体
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
WO2015095412A1 (en) * 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
RU2609627C2 (ru) 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MA41375A (fr) 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
IL262241B2 (en) 2016-04-13 2024-05-01 Sanofi Sa Trispecific and/or trivalent binding proteins with a crossover dual variable domain arm and a traditional antibody fab arm, pharmaceutical composition comprising said binding proteins and their uses in preventing and/or treating cancer or inflammatory diseases
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100331527A1 (en) * 2009-06-26 2010-12-30 Regeneron Pharmaceuticals, Inc. Readily Isolated Bispecific Antibodies with Native Immunoglobulin Format
WO2013064701A2 (en) * 2011-11-03 2013-05-10 Argen-X B.V. Bispecific antibodies and methods for isolating same
WO2014022540A1 (en) * 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
WO2014124326A1 (en) * 2013-02-08 2014-08-14 Stem Centrx, Inc. Novel multispecific constructs
WO2015033223A2 (en) * 2013-09-03 2015-03-12 Novimmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
WO2016086189A2 (en) * 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
WO2016086186A2 (en) * 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies including binding to cd8
WO2017218707A2 (en) * 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M. MUDA ET AL: "Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies", PROTEIN ENGINEERING DESIGN AND SELECTION, vol. 24, no. 5, 15 April 2011 (2011-04-15), pages 447 - 454, XP055193599, ISSN: 1741-0126, DOI: 10.1093/protein/gzq123 *
STEVEN M LEWIS ET AL: "Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface", NATURE BIOTECHNOLOGY, vol. 32, no. 2, 1 February 2014 (2014-02-01), New York, pages 191 - 198, XP055240003, ISSN: 1087-0156, DOI: 10.1038/nbt.2797 *

Also Published As

Publication number Publication date
DK3728328T3 (da) 2025-01-02
JP2023139025A (ja) 2023-10-03
EP4495142A2 (en) 2025-01-22
AU2018387829A1 (en) 2020-05-07
JP2021506310A (ja) 2021-02-22
EP3728328A1 (en) 2020-10-28
CN111448217A (zh) 2020-07-24
CA3079793A1 (en) 2019-06-27
DK3728328T5 (da) 2025-02-17
EP3728328B1 (en) 2024-10-23
IL274676A (en) 2020-06-30
US20190218310A1 (en) 2019-07-18
US20240368311A1 (en) 2024-11-07
AU2018387829B2 (en) 2024-12-19
WO2019122409A1 (en) 2019-06-27
US12071486B2 (en) 2024-08-27
JP7657591B2 (ja) 2025-04-07

Similar Documents

Publication Publication Date Title
NZ732628A (en) Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof
EP4495142A3 (en) Bispecific antigen binding construct
AU2014232501C1 (en) Heterodimeric proteins
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
EP4516809A3 (en) Bispecific antibodies specifically binding to pd1 and lag3
AU2018258045A1 (en) Chimeric antibody/T-cell receptor constructs and uses thereof
EP4640705A3 (en) Anti-tl1a antigen binding proteins and uses thereof
WO2019086500A3 (en) Bispecific 2+1 contorsbodies
UY37694A (es) Dominios de unión a antígeno humanizados y métodos de uso
WO2019005637A3 (en) Multi-specific antibodies and methods of making and using thereof
WO2019241430A3 (en) Antibody-oligonucleotide conjugates
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
WO2017132562A8 (en) Antigen binding proteins that bind pd-l1
MX2019000730A (es) Proteinas multiespecificas de union al antigeno y metodos de uso de estas.
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
MY194994A (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
MX2015012540A (es) Ratón de cadena ligera común.
HK1249048A1 (zh) 靶向afp肽/mhc复合体的构建体及其用途
AR105267A1 (es) Anticuerpos de unión a tau
HK1208994A1 (en) Methods for making fully human bispecific antibodies using a common light chain
MX2016006301A (es) Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos.
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
EP4253959A3 (en) Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule
SG10201801219VA (en) Anti-HER2 Antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3728328

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/46 20060101AFI20250331BHEP

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20251108